Eckert & Ziegler Strahlen- und Medizintechnik AG / Quarter Results
04.05.2010 07:46
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, May 4, 2010 - Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a firm specializing in medical use
of radioactivity, increased its profit after taxes and minority interests
to EUR 2.5 million in the first quarter of 2010, an increase of 17% over
the first quarter of 2009 and an increase of 35% when compared to the
operating quarterly average in 2009. In spite of a 36% increase in the
number of shares in comparison to 2009, earnings per share remained
constant at EUR 0.49 (operating average per quarter in 2009: EUR 0.49 /
share). The Berlin-based group recorded a slight increase in sales to EUR
25.7 million (previous year's quarter: EUR 24.3 million).
The most successful segment was again the Industry segment. Revenue
increased by 13%, the unadjusted margin by 34% and the EBIT by 91% to EUR
4.3 million. The successful integration of Nuclitec continues. The
synergies become obvious once restructuring expenses no longer apply. The
segment was also able to report strong shipments of high-margin robust
drill hole sources. Environmental Services, which relate to taking back,
reprocessing, recycling and disposal of low level radioactive waste, are
still included in the Industry segment for comparison purposes. No new
business was expected here in the first quarter of 2010, and with EUR 1.3
million in sales and expenses for preparations for new business that led to
a small loss of EUR 46,000, this area developed within the framework of
expectations. The annual sales target of the existing business (taking back
sources and disposal of low level radioactive hospital waste) is EUR 5
million. In the segment reporting of the I/2010 quarterly report, the
numbers for the new 'Environmental Services' segment are shown separately
for the first time.
With sales of EUR 6.4 million and an EBIT of EUR 0.6 million, the Therapy
segment experienced a quarter that was slightly below average. The relative
reduction in sales in the first quarter of a year is normal and is based on
strong sales in the last quarter of 2009. Sales and income from the Russian
project are also absent, but will surely contribute to results in the rest
of the year. Since the takeover bid and the accompanying increase in IBt
shares did not become effective until the middle of March 2010, no
significant reduction in minority interests could be recorded. On the
contrary, the first quarter includes one time extraordinary expenses of 0.3
mm EUR for take-over bid cost.
The Radiopharmaceuticals segment is at the level of the previous year in
terms of revenue and its cost positions. Half of the considerable increase
in EBIT to EUR 0.7 million can be traced to income from transfers of shares
and borrowings from Eckert & Ziegler EURO-PET Berlin GmbH.
The Executive Board and Supervisory Board will propose an increase in
dividends from EUR 0.30 to EUR 0.45 per share at the Annual General Meeting
on May 20, 2010.
For the current year, the company expects a result of around EUR 1.80 /
share with a 40% increase in the number of shares. If the increase in the
number of shares is not taken into account, this would correspond to growth
of around 28%.
The Eckert & Ziegler Group, with around 520 employees, is one of the
world's largest providers of isotope technology components for radiotherapy
and nuclear medicine.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-mail: karolin.riehle@ezag.de, www.ezag.com
04.05.2010 07:46 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Eckert & Ziegler: Earnings Increase Again After Restructuring Expenses No Longer Apply
| Source: EQS Group AG